Melanoma Detection in Switzerland With VECTRA

CompletedOBSERVATIONAL
Enrollment

455

Participants

Timeline

Start Date

January 25, 2021

Primary Completion Date

January 31, 2024

Study Completion Date

January 31, 2024

Conditions
Melanoma (Skin)
Interventions
DEVICE

3D imaging Total Body Photography Vectra® WB360

3D Total Body Photography Vectra® WB360 (Canfield Scientific, Parsippany, New Jersey, USA) and its digital dermoscopic camera (VISIOMED® D200evo dermatoscope) and scoring of pigmented skin lesions. All participants of this study will undergo 3D TBP at baseline and the follow-up visits up to month 24.

DEVICE

2D imaging FotoFinder ATBM® Master imaging system

2D imaging with FotoFinder® Mole Analyzer and scoring of pigmented skin lesions. All participants of this study will undergo 2D imaging FotoFinder ATBM® Master imaging system at baseline and the follow-up visits up to month 24.

DEVICE

Smartphone application (SkinVision®)

Smartphone application for all dermatoscopically documented pigmented skin lesions in all study participations and record of risk assessment of the health application (low, medium or high risk) to compare the app's accuracy in risk assessment with the AI tools and the dermatologist. The SkinVision® smartphone app is CE certified.of skin lesions. All participants of this study will undergo Smartphone application (SkinVision®) at baseline and the follow-up visits up to month 12.

OTHER

Standard-of-care clinical assessment of the skin

Clinical skin examination with dermatoscope by an experienced dermatologist and risk assessment of pigmented lesions (melanoma vs. naevus). All participants of this study will undergo Standard-of-care clinical assessment of the skin at baseline and the follow-up visits up to month 24.

Trial Locations (1)

4031

Department of Dermatology, University Hospital Basel, Basel

All Listed Sponsors
lead

University Hospital, Basel, Switzerland

OTHER

NCT04605822 - Melanoma Detection in Switzerland With VECTRA | Biotech Hunter | Biotech Hunter